drugset / Trial / NCT02753712
A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to demonstrate improvement of peripheral airway resistance (R5-R20) from baseline with fluticasone/formoterol breath actuated inhaler (BAI).
Timeline
- Start
- 2016-06-15
- Primary completion
- 2017-08-14
- Completion
- 2017-08-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fluticasone | Other / unclassified | 92 ug | Inhaled |
| Comparator | Fluticasone | Other / unclassified | 125 ug | Inhaled |
| Subject | Formoterol | Other / unclassified | 5 ug | Inhaled |
| Comparator | Vilanterol | Other / unclassified | 22 ug | Inhaled |